# A Study of CA201A Eye Drops to Prevent Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery

> **NCT07694375** · PHASE2 · RECRUITING · sponsor: **Caravel Oculus Pty Ltd** · enrollment: 200 (estimated)

## Conditions studied

- Corneal Endothelial Cell Loss
- Corneal Endothelial Damage Following the Hard Nuclear Cataract Surgery

## Interventions

- **DRUG:** Ophthalmic solution (matching formulation without ascorbic acid)
- **DRUG:** Ascorbic acid ophthalmic solution 5%

## Key facts

- **NCT ID:** NCT07694375
- **Lead sponsor:** Caravel Oculus Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-28
- **Primary completion:** 2027-01
- **Final completion:** 2027-02
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07694375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07694375, "A Study of CA201A Eye Drops to Prevent Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07694375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*